In our systematic analysis, synchronous combination therapy of chemotherapy and EGFR TKIs failed to significantly improve OS, TTP and ORR, compared with chemotherapy monotherapy or EGFR TKIs in patients with advance NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.